During the corresponding time, Arcus Biosciences Inc saw a revenue deteriorated by -74.38 % year on year, sequentially revenue grew by 141.18 %. While revenue at the Arcus Biosciences Inc 's corporate clients
In a significant development for the treatment of non-small cell lung cancer (NSCLC), Arcus Biosciences, Inc. (NYSE: RCUS) has announced that its combination therapy, featuring Domvanalimab and Zimberelimab, has demonstrated improved overall survival rates in patients with PD-L1-high NSCLC. This milestone was unveiled as part of the interim results from the ARC-10 randomized study, a promising step forward in the quest to enhance outcomes for one of the most common and challenging types of lung cancer.Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with NSCLC accounting for approximately 85% of all lung cancer cases. Among the various treatment options, targeted immunothe...
HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE: RCUS), a leading clinical-stage global biopharmaceutical company, has announced a pivotal clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN). This partnership aims to evaluate the potential efficacy of casdatifan (AB521), Arcus s investigational HIF-2α inhibitor, when combined with volrustomig, AstraZeneca s investigational PD-1/CTLA-4 bispecific antibody, in patients with renal cell carcinoma.This advanced collaboration represents a significant stride in the realm of oncology, targeting renal cell carcinoma, a type of kidney cancer notorious for its resistance to conventional treatments. By leveraging the distinct mechanisms of ac...
In a groundbreaking development, Arcus Biosciences, a leading global biopharmaceutical company, has recently announced the successful completion of patient enrollment for STAR-221, a crucial Phase 3 clinical trial in collaboration with Gilead Sciences. This study aims to evaluate the effectiveness of a promising combination therapy, involving the Fc-silent anti-TIGIT antibody domvanalimab, the anti-PD-1 monoclonal antibody zimberelimab, and chemotherapy. The implications of this milestone for Arcus Biosciences and the potential impact on the field of cancer treatment are substantial. Arcus Biosciences completion of patient enrollment for the Phase 3 trial, STAR-221, stands as a significant achievement in th...
Arcus Biosciences (NYSE: RCUS), a renowned clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through the development of innovative molecules and combination therapies, recently held a conference call and webcast to discuss their remarkable first-quarter 2024 financial results and provide updates on their pipeline. The management team of Arcus Biosciences hosted the call on Wednesday, May 8th, 2024, at 1:30 PM PT / 4:30 PM ET, engaging investors and stakeholders in an insightful conversation.During the conference call, Arcus Biosciences reflected on their exceptional financial performance for the quarter ended March 31st, 2024. The company demonstrated its continued succes...
In the continuous odyssey of medical research, a glimmer of hope emerges as new findings on Quemliclustat-based regimens show encouraging overall survival data in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). ARC-8, a Phase 1b study carried out by Arcus Biosciences, in partnership with Gilead Sciences, has highlighted the potential of Quemliclustat in the fight against pancreatic cancer. Pancreatic cancer is a notoriously difficult disease to combat, traditionally presenting poor survival rates and daunting prognoses. This revelation from Arcus Biosciences signals an important step towards flipping the script and defeating such a formidable foe. The study, which delves into the...
Sources:
Arcus Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Arcus Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Arcus Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
4.88 %